242,392 Shares in Dyne Therapeutics, Inc. $DYN Acquired by Deutsche Bank AG

Deutsche Bank AG purchased a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 242,392 shares of the company's stock, valued at approximately $5,384,000. Deutsche Bank AG owned approximately 0.13% of Dyne Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the business. T. Rowe Price Investment Management Inc. grew its holdings in Dyne Therapeutics by 523.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company's stock worth $343,085,000 after acquiring an additional 14,727,667 shares during the period. Vanguard Group Inc. lifted its holdings in Dyne Therapeutics by 14.9% in the 4th quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company's stock valued at $219,376,000 after acquiring an additional 1,455,151 shares during the last quarter. State Street Corp boosted its position in shares of Dyne Therapeutics by 27.0% during the 4th quarter. State Street Corp now owns 6,692,745 shares of the company's stock valued at $130,910,000 after purchasing an additional 1,423,828 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Dyne Therapeutics by 45.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company's stock valued at $101,164,000 after purchasing an additional 1,618,000 shares in the last quarter. Finally, Orbis Allan Gray Ltd acquired a new position in shares of Dyne Therapeutics in the 4th quarter worth approximately $93,926,000. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock opened at $25.99 on Tuesday. Dyne Therapeutics, Inc. has a 12 month low of $11.92 and a 12 month high of $27.31. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28. The stock has a market cap of $4.85 billion, a PE ratio of -7.80 and a beta of 1.07. The business has a fifty day simple moving average of $23.83 and a 200-day simple moving average of $19.83.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.47 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on DYN. TD Cowen began coverage on Dyne Therapeutics in a research report on Friday, June 26th. They set a "buy" rating on the stock. Sanford C. Bernstein increased their price target on Dyne Therapeutics from $23.00 to $24.00 and gave the company a "market perform" rating in a research report on Wednesday, May 13th. HC Wainwright reissued a "buy" rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Monday, August 17th. Wall Street Zen downgraded Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 1st. Finally, Royal Bank Of Canada upped their price objective on shares of Dyne Therapeutics from $30.00 to $35.00 and gave the company an "outperform" rating in a research note on Thursday, July 30th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Dyne Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $34.42.

Insider Buying and Selling

In other Dyne Therapeutics news, Director Brian S. Posner bought 2,500 shares of the firm's stock in a transaction on Wednesday, June 3rd. The stock was bought at an average cost of $17.48 per share, with a total value of $43,700.00. Following the completion of the transaction, the director directly owned 22,500 shares of the company's stock, valued at approximately $393,300. The trade was a 12.50% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jason P. Rhodes sold 2,160,516 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the transaction, the director owned 428,946 shares in the company, valued at approximately $10,723,650. This trade represents a 83.43% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 4,139,196 shares of company stock worth $99,449,852 in the last 90 days. 9.46% of the stock is currently owned by corporate insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source